<DOC>
	<DOCNO>NCT01497834</DOCNO>
	<brief_summary>The purpose study assess anti-viral activity BMS-790052 BMS-650032 combination therapy Japanese subject .</brief_summary>
	<brief_title>A Phase 3 Study Combination With BMS-790052 BMS-650032 Japanese Hepatitis C Virus ( HCV ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Chronic HCV1b infect patient HCV RNA viral load â‰¥ 100,000 IU/mL screening Ages 20 75 year Nonresponder Interferon plus Ribavirin therapy Patient exclude interferon/ribavirin therapy intolerant Interferon/Ribavirin therapy Patients Hepatocellular carcinoma Coinfection Hepatitis B virus ( HBV ) Human Immunodeficiency Virus ( HIV ) Severe uncontrollable complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hepatitis C Virus Infection</keyword>
</DOC>